Qatar Investment Authority (QIA) has invested in an innovative healthcare company, Kardium, the developer of the Globe Pulsed Field System, an innovative treatment for atrial fibrillation (AF).
QIA said in a press statement that Kardium has raised $250 million in a new financing round. QIA was joined by other new investors, Janus Henderson Investors, MM Capital, Piper Heartland Healthcare Capital, Eventide Asset Management, and Eckuity Capital in leading the round.
Existing investors also participated, including funds and accounts advised by T Rowe Price Associates, T Rowe Price Investment Management, and Durable Capital Partners LP. The financing also includes an equity investment from a leading strategic investor.
“We’re thrilled to have secured this transformational financing with a world-class syndicate of investors. This funding enables us to move ahead with the commercial launch of the Globe System by expanding our manufacturing capabilities and building a strong commercial team. Everyone at Kardium is energised by the opportunity to bring the Globe System to market and help improve the lives of millions of patients worldwide suffering from atrial fibrillation.”
The new funding will enable Kardium to pursue regulatory approvals for the Globe System, further expand its manufacturing facilities and production capacity, and establish a clinical support and commercial team in preparation for the anticipated commercial launch of the Globe System later this year.
The Globe Pulsed Field System consists of a sophisticated catheter with a 122-electrode array and advanced software that enables rapid pulmonary vein isolation, high-definition mapping, and the ability to ablate anywhere in the atrium, all with a single catheter.
